. 2014 Feb 11;13(4):1137–1149. doi: 10.1074/mcp.M113.034660

Table I. Target proteins and their signature peptides for MRM-MS assay development. Unlabeled and corresponding [¹³C] or [¹³C¹⁵N] labeled peptides were synthesized for optimization and employment of stable isotope dilution multiple reaction monitoring mass spectrometry.

Protein	Signature Peptide	MH+ (mono)	z (Q1)	MRM Transitions
Protein	Signature Peptide	MH+ (mono)	z (Q1)	Q1	Q3
AEBP1	ILNPGEYR^a	961.51	2	481.26	524.25	621.3	735.34
	ILNPGEY[¹³C₆]R^a	967.53	2	484.27	530.27	627.32	741.36
	NPFVLGANLNGGER^a	1457.75	2	729.38	887.43	1000.52	1099.59
	NPFVLGANLNGGE[¹³C₆]R^a	1463.77	2	732.39	893.45	1006.54	1105.61
	DTPVLSELPEPVVAR^a	1621.88	2	811.44	767.44	880.53	1096.60
	DTPVLSELPEPVVA[¹³C₆]R^a	1627.90	2	814.45	773.46	886.55	1102.62
	VVNEEC_amcPTITR^a	1317.65	2	659.33	587.35	747.38	1119.51
	VVNEEC_amcPTIT[¹³C₆]R^a	1323.67	2	662.34	593.37	753.40	1125.53
APR	AGLC_amcQTFVYGGC_amcR^a,b	1488.68	2	744.84	858.39	959.44	1087.50
APR	AGLC_amcQTF[¹³C₅]VYGGC_amcR^a,b	1493.70	2	747.35	863.41	964.46	1092.52
BNP	MVQGSGC_amcFGR^a,b	1098.49	2	549.74	683.29	740.31	868.37
	M[¹³C₅]VQGSGC_amcFGR^a,b	1103.51	2	552.25	683.29	740.31	868.37
	M_{oxVQGSGC_amc}FGR^a,b	1114.48	2	557.74	683.29	740.31	868.37
	M_ox[¹³C₅]VQGSGC_amcFGR^a,b	1119.50	2	560.25	683.29	740.31	868.37
	ISSSSGLGC_amcK^a,b	995.49	2	498.24	708.33	795.37	882.40
	ISSSSGLGC_amc[¹³C₆]K^a,b	1001.51	2	501.26	714.35	801.39	888.42
CRP	ESDTSYVSLK^b	1128.50	2	564.77	609.36	696.39	797.44
	ESDTSYVSL[¹³C₆]K^b	1134.60	2	567.78	615.38	702.41	803.46
	GYSIFSYATK^b	1136.60	2	568.78	716.36	829.45	916.48
	GYSIFSYAT[¹³C₆]K^b	1142.60	2	571.79	722.38	835.47	922.50
FHL1	AIVAGDQNVEYK^a	1306.66	2	653.84	952.44	1023.47	1122.54
	AIVAGDQNVEY[¹³C₆]K^a	1312.68	2	656.85	958.46	1029.49	1128.56
	NPITGFGK^a	833.45	2	417.23	408.22	509.27	622.36
	NPITGFG[¹³C₆]K^a	839.47	2	420.24	414.24	515.29	628.38
	FC_amcANTC_amcVEC_amcR^a	1316.52	2	658.76	824.34	938.38	1009.42
	FC_amcANTC_amcVEC_amc[¹³C₆]R^a	1322.54	2	661.77	830.36	944.40	1015.44
	DC_amcFTC_amcSNC_amcK^a	1191.42	2	596.22	508.22	668.25	769.30
	DC_amcFTC_amcSNC_amc[¹³C₆]K^a	1197.44	2	599.22	514.24	674.27	775.32
HRP	DTIVNELR^a,b	959.52	2	480.26	531.29	630.36	743.44
HRP	DTIVNE[¹³C₆]LR^a,b	965.54	2	483.27	537.31	636.38	749.46
IL-33	DFWLHANNK^a,b	763.38	3	382.19	441.73	583.29	696.38
	DFW[¹³C₆]LHANNK^a,b	767.39	3	384.20	444.74	583.29	702.40
	DNHLALIK^a,b	923.54	2	462.27	480.22	551.26	664.34
	DNHLA[¹³C₆]LIK^a,b	929.56	2	465.28	480.22	551.26	670.36
	TDPGVFIGVK^a,b	1032.58	2	516.79	662.42	719.45	816.50
	TDPGVFIGV[¹³C₆]K^a,b	1038.60	2	519.80	668.44	725.47	822.52
LEP	INDISHTQSVSAK^a,b	1399.73	3	467.24	543.28	586.80	643.82
LEP	INDISHTQS[¹³C₆]VSAK^a,b	1404.75	3	468.92	543.28	589.31	646.33
MBP	HGFLPR^a	726.41	2	363.71	385.26	532.32	589.35
	HGF[¹³C₆]LPR^a	732.43	2	366.72	391.28	538.34	595.37
	YLASASTMDHAR^a,b	1322.63	3	441.54	488.22	523.74	817.36
	Y[¹³C₆]LASASTMDHAR^a,b	1328.65	3	443.55	488.22	523.74	817.36
MPO	IPC_{amcFLAGDTR^a,b}	1149.58	2	575.29	632.34	779.40	939.44
	IPC_amcF[¹³C₆]LAGDTR^a,b	1155.60	2	578.30	638.36	785.42	945.46
	IANVFTNAFR^a,b	1152.62	2	576.81	755.38	854.45	968.49
	IANVFTNAF[¹³C₆]R^a,b	1158.64	2	579.82	761.40	860.47	974.51
MYO	LFTGHPETLEK^a	1271.68	3	424.56	506.26	579.79	716.38
MYO	LFTGHPET[¹³C₆]LEK^a	1277.70	3	426.57	509.27	582.80	722.40
MYL3	AAPAPAPPPEPERPK^a	1524.82	2	762.91	626.36	1046.56	1214.65
	AAPAPAPPPEPERP[¹³C₆]K^a	1530.84	2	765.92	632.38	1032.58	1220.67
	ALGQNPTQAEVLR^a	1396.75	2	698.88	715.41	913.51	1027.55
	ALGQNPTQAEVL[¹³C₆]R^a	1402.77	2	701.89	721.43	919.53	1033.57
	EVEFDASK^a	924.43	2	462.72	420.21	567.28	696.32
	EVEFDAS[¹³C₆]K^a	930.45	2	465.73	426.23	573.3	702.34
	HVLATLGER^a	995.56	2	498.29	646.35	759.44	858.50
	HVLATLGE[¹³C₆]R^a	1001.58	2	501.30	652.37	765.46	864.52
NT-proBNP	M_oxVLYTLR^a,b	911.51	2	456.25	552.31	665.40	764.47
	M_oxVLYT[¹³C₆]LR^a,b	917.53	2	459.26	558.33	671.42	770.49
	MVLYTLR^a,b	895.51	2	448.26	552.31	665.40	764.47
	MVLYT[¹³C₆]LR^a,b	901.53	2	451.27	558.33	671.42	770.49
	EVATEGIR^a,b	874.47	2	437.74	474.27	575.31	646.35
	EVATEG[¹³C₆]IR^a,b	880.49	2	440.75	480.29	581.33	652.37
PSA	LSEPAELTDAVK^a,b	1272.68	2	636.84	775.42	846.46	943.51
	LSEPAELTDAV[¹³C₆]K^a,b	1278.70	2	639.85	781.44	852.48	949.53
	IVGGWEC_amcEK^a,b	1077.51	2	539.26	808.33	865.35	964.42
	IVGGWEC_amcE[¹³C₆]K^a,b	1083.53	2	542.27	814.35	871.37	970.44
sCD40L	SLSLLNC_amcEEIK^a,b	1305.68	2	653.34	792.36	905.44	1105.56
	SLSLLNC_amcEE[¹³C₆]IK^a,b	1311.70	2	656.35	798.38	911.46	1111.58
	SQFEGFVK^a,b	941.48	2	471.24	579.31	726.38	854.44
	SQFEGF[¹³C₆]VK^a,b	946.50	2	473.75	584.33	731.40	859.46
	TTSVLQWAEK^a,b	1162.62	2	581.81	661.33	774.41	960.51
	TTSV[¹³C₆]LQWAEK^a,b	1168.64	2	584.82	661.33	780.43	966.54
	EASSQAPFIASLC_amcLK^a,b	1621.83	2	811.42	691.38	1048.59	1119.62
	EASSQAPFIASLC_amc[¹³C₆]LK^a,b	1627.85	2	814.43	697.40	1054.61	1125.64
Tropomyosin 1	QLEDELVSLQK^a,b	1301.69	2	651.35	687.44	816.48	931.51
	QLEDELVSLQ[¹³C₆¹⁵N₂]K^a,b	1309.71	2	655.36	695.45	824.5	939.52
	LVIIESDLER^a,b	1186.67	2	593.84	748.35	861.43	974.52
	LVIIESDLE[¹³C₆¹⁵N₄]R^a,b	1196.68	2	598.84	758.36	871.44	984.52
Troponin I	NIDALSGMEGR^a,b	1162.56	2	581.78	636.28	749.36	935.43
	NIDA[¹³C₆]LSGMEGR^a,b	1168.58	2	584.79	636.28	755.38	941.45
	TLLLQIAK^a,b	899.60	2	450.30	459.29	572.38	685.46
	TLLLQIA[¹³C₆]K^a,b	905.62	2	453.31	465.31	578.40	691.48
	NITEIADLTQK^a,b	1245.68	2	623.34	675.37	788.45	1018.54
	NITEIADLTQ[¹³C₆]K^a,b	1251.70	2	626.35	681.39	794.47	1024.56
Troponin T	VLAIDHLNEDQLR^a,b	1535.82	3	512.61	662.34	718.88	774.37
	VLAIDHLNEDQ[¹³C₆]LR^a,b	1541.84	3	514.62	665.35	721.89	780.39
	YEINVLR^a,b	906.50	2	453.76	501.31	614.4	743.44
	YEINV[¹³C₆]LR^a,b	912.52	2	456.77	507.33	620.42	749.46

Notes: Uniformly labeled amino acids are indicated in bold. Camc, carbamidomethyl cysteines; Mox, methionine sulfoxide.

^a Peptides used in the main LOD/LOQ comparison and background studies.

^b Peptides used in all of the chromatography optimization experiments.

Table I. Target proteins and their signature peptides for MRM-MS assay development. Unlabeled and corresponding [13C] or [13C15N] labeled peptides were synthesized for optimization and employment of stable isotope dilution multiple reaction monitoring mass spectrometry.

Table I. Target proteins and their signature peptides for MRM-MS assay development. Unlabeled and corresponding [¹³C] or [¹³C¹⁵N] labeled peptides were synthesized for optimization and employment of stable isotope dilution multiple reaction monitoring mass spectrometry.